Compare GABC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | PRCT |
|---|---|---|
| Founded | 1910 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2021 |
| Metric | GABC | PRCT |
|---|---|---|
| Price | $41.25 | $26.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $46.50 | $35.44 |
| AVG Volume (30 Days) | 128.3K | ★ 2.0M |
| Earning Date | 04-27-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 8.13 | 1.71 |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $487,401,000.00 | $308,054,000.00 |
| Revenue This Year | $17.03 | $31.62 |
| Revenue Next Year | $3.92 | $24.45 |
| P/E Ratio | $13.61 | ★ N/A |
| Revenue Growth | ★ 37.80 | 37.22 |
| 52 Week Low | $32.75 | $19.35 |
| 52 Week High | $45.00 | $64.89 |
| Indicator | GABC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 50.60 |
| Support Level | $37.28 | $19.35 |
| Resistance Level | $42.40 | $29.06 |
| Average True Range (ATR) | 0.86 | 1.58 |
| MACD | 0.20 | 0.09 |
| Stochastic Oscillator | 72.78 | 55.22 |
German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.